Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.
JGH Open
; 5(7): 778-784, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-34263072
ABSTRACT
BACKGROUND AND AIM:
Quinolones are a potent and globally popular group of antibiotics that are used to treat a wide range of infections. Some case reports have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.METHODS:
AHF reports between 1969 and 2019q2, with a focus on 2010-2019q2, were analyzed. Specifically, AHF reports linked to non-quinolone antibiotics of known hepatotoxicity were compared to reports with non-quinolone, non-hepatotoxic (reference) antibiotics; and AHF reports with quinolones were also compared to reports with the same group of reference antibiotics. Two disproportionality signal detection techniques (proportional reporting ratio, PRR, and empirical Bayes geometric mean, EBGM) were used to assess the AHF signal for both analyses.RESULTS:
Only ciprofloxacin showed a marginal and significant AHF signal (PRR 1.85 [1.21, 2.81]; EBGM 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.CONCLUSION:
Further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
JGH Open
Ano de publicação:
2021
Tipo de documento:
Article